Literature DB >> 23756389

The impact of physical activity and nutrition on inflammatory bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle.

J Bilski1, A I Mazur-Bialy, M Wierdak, T Brzozowski.   

Abstract

Crohn's disease and ulcerative colitis are both chronic inflammatory bowel diseases (IBDs) characterized by a cyclical nature, which alternates between active and quiescent states, ultimately impairing a patients' quality of life. The etiology of IBD is not known but it likely involves a combination of genetic predisposition and environmental risk factors. Physical exercise has been suggested to provide protection against the onset of IBD, but there are inconsistencies in the findings of the published literature. Current research recommends exercise to help counteract some IBD-specific complications and preliminary studies suggest that physical activity may be beneficial in reducing the symptoms of IBD. Obesity is becoming more prevalent in patients diagnosed with IBD and may be associated with higher disease activity. There is evidence that adipokines are involved in the inflammatory and metabolic pathways. Hypertrophy of the mesenteric white adipose tissue has been long recognized as a characteristic feature of Crohn's disease; however its importance is unknown. Recent data suggest that dysregulation of adipokine secretion by white adipose tissue is involved in the pathogenesis of Crohn's disease. Skeletal muscle was shown to produce biologically active myokines, which could be a important contributor to the beneficial effects of exercise. There is mounting evidence for the bi-directional endocrine cross talk between adipose tissue and skeletal muscle. The objective of the present review is to explore the role of exercise and its impact on IBD. Also, we discuss how current discoveries regarding the importance of adipokines and myokines and their cross talk expand our view of the pathological changes and the therapeutic options for IBD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756389

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  25 in total

1.  Myokine IL-15 regulates the crosstalk of co-cultured porcine skeletal muscle satellite cells and preadipocytes.

Authors:  Yinghui Li; Fengna Li; Binbin Lin; Xiangfeng Kong; Yulong Tang; Yulong Yin
Journal:  Mol Biol Rep       Date:  2014-08-07       Impact factor: 2.316

2.  Exercise and Self-Reported Limitations in Patients with Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Saniya Tabani; Ryan U Warren; Paul J Christos; Brian P Bosworth; Ellen J Scherl
Journal:  Dig Dis Sci       Date:  2015-08-09       Impact factor: 3.199

3.  Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease.

Authors:  Nik Sheng Ding; Daniel Tassone; Ibrahim Al Bakir; Kyle Wu; Alexander J Thompson; William R Connell; George Malietzis; Phillip Lung; Siddharth Singh; Chang-Ho Ryan Choi; Simon Gabe; John T Jenkins; Ailsa Hart
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020

4.  Moderate exercise training attenuates the severity of experimental rodent colitis: the importance of crosstalk between adipose tissue and skeletal muscles.

Authors:  Jan Bilski; Agnieszka I Mazur-Bialy; Bartosz Brzozowski; Marcin Magierowski; Katarzyna Jasnos; Gracjana Krzysiek-Maczka; Katarzyna Urbanczyk; Agata Ptak-Belowska; Malgorzata Zwolinska-Wcislo; Tomasz Mach; Tomasz Brzozowski
Journal:  Mediators Inflamm       Date:  2015-01-05       Impact factor: 4.711

5.  Self-Care Among Patients With Inflammatory Bowel Disease: An Interview Study.

Authors:  Ulrica Lovén Wickman; Pia Yngman-Uhlin; Henrik Hjortswang; Barbara Riegel; Henrik Stjernman; Gunilla Hollman Frisman
Journal:  Gastroenterol Nurs       Date:  2016 Mar-Apr       Impact factor: 0.978

6.  Beneficial Effect of Voluntary Exercise on Experimental Colitis in Mice Fed a High-Fat Diet: The Role of Irisin, Adiponectin and Proinflammatory Biomarkers.

Authors:  Agnieszka Irena Mazur-Bialy; Jan Bilski; Dagmara Wojcik; Bartosz Brzozowski; Marcin Surmiak; Magdalena Hubalewska-Mazgaj; Anna Chmura; Marcin Magierowski; Katarzyna Magierowska; Tomasz Mach; Tomasz Brzozowski
Journal:  Nutrients       Date:  2017-04-20       Impact factor: 5.717

7.  A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.

Authors:  Vibeke Andersen; Uffe Holmskov; Signe Bek Sørensen; Mohamad Jawhara; Karina W Andersen; Anette Bygum; Lone Hvid; Jakob Grauslund; Jimmi Wied; Henning Glerup; Ulrich Fredberg; Jan Alexander Villadsen; Søren Geill Kjær; Jan Fallingborg; Seyed A G R Moghadd; Torben Knudsen; Jacob Brodersen; Jesper Frøjk; Jens F Dahlerup; Ole Haagen Nielsen; Robin Christensen; Anders Bo Bojesen; Grith Lykke Sorensen; Steffen Thiel; Nils J Færgeman; Ivan Brandslund; Allan Stensballe; Erik Berg Schmidt; Andre Franke; David Ellinghaus; Philip Rosenstiel; Jeroen Raes; Berit Heitmann; Mette Boye; Charlotte Lindgaard Nielsen; Lars Werner; Jens Kjeldsen; Torkell Ellingsen
Journal:  Nutrients       Date:  2017-05-15       Impact factor: 5.717

8.  Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation.

Authors:  Lana Claudinez dos Santos; Aline Villela Costa; Lorrayne Gonçalves Lopes; Alda Jusceline Leonel; Edenil Costa Aguilar; Maria de Lourdes Meirelles Noviello; Maria de Lourdes de Abreu Ferrari; Jacqueline I Alvarez-Leite
Journal:  Med Sci Monit       Date:  2015-08-07

Review 9.  The role of physical exercise in inflammatory bowel disease.

Authors:  Jan Bilski; Bartosz Brzozowski; Agnieszka Mazur-Bialy; Zbigniew Sliwowski; Tomasz Brzozowski
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

Review 10.  Interaction of obesity and inflammatory bowel disease.

Authors:  Jason W Harper; Timothy L Zisman
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.